Tags

Type your tag names separated by a space and hit enter

Quality of life assessment in patients with chronic pancreatitis receiving antioxidant therapy.
World J Gastroenterol 2010; 16(32):4066-71WJ

Abstract

AIM

To undertake a baseline study comparing quality of life (QoL) in patients with chronic pancreatitis (CP) on Antox to those with CP, matched for disease duration, who were not on this medication.

METHODS

CP was defined according to the Zurich classification. Sixty eight consecutive patients with CP who were taking Antox (antioxidants) were compared with 69 consecutive control CP patients not on Antox. European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core questions 30 and Pancreatic Modification (28 questions) were used to assess QoL. Out of a total of 137 patients 28 in each group were matched for disease duration (within 12 mo). Median disease duration was 8 (1-22) years in the Antox group and 7 (1-23) years in the Non-Antox cohort (P = NS, Mann-Whitney U-test). Other parameters (age, gender, etiology, endocrine and exocrine insufficiency) were similar between groups.

RESULTS

Median visual analogue pain score in the Antox group was 3 (0-8) compared with 6 (0-8) in the Non-Antox group (P < 0.01). Perceptions of cognitive, emotional, social, physical and role function were impaired in the Non-Antox group compared to Antox patients (P < 0.0001, P = 0.0007, P = 0.0032 and P < 0.005 and P < 0.001, respectively). Analgesics and opiate usage was significantly lower in the Antox group (P < 0.01). Overall physical health and global QoL was better in the Antox group (P < 0.0001, 95% CI: 1.5-3).

CONCLUSION

Contemporary quality of life assessments show that after correction for disease duration and cigarette smoking, patients with CP taking antox had better scores than non-antox controls.

Authors+Show Affiliations

Hepatobiliary Surgery Unit, Manchester Royal Infirmary, Oxford Road, Manchester, United Kingdom.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20731021

Citation

Shah, Nehal S., et al. "Quality of Life Assessment in Patients With Chronic Pancreatitis Receiving Antioxidant Therapy." World Journal of Gastroenterology, vol. 16, no. 32, 2010, pp. 4066-71.
Shah NS, Makin AJ, Sheen AJ, et al. Quality of life assessment in patients with chronic pancreatitis receiving antioxidant therapy. World J Gastroenterol. 2010;16(32):4066-71.
Shah, N. S., Makin, A. J., Sheen, A. J., & Siriwardena, A. K. (2010). Quality of life assessment in patients with chronic pancreatitis receiving antioxidant therapy. World Journal of Gastroenterology, 16(32), pp. 4066-71.
Shah NS, et al. Quality of Life Assessment in Patients With Chronic Pancreatitis Receiving Antioxidant Therapy. World J Gastroenterol. 2010 Aug 28;16(32):4066-71. PubMed PMID: 20731021.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Quality of life assessment in patients with chronic pancreatitis receiving antioxidant therapy. AU - Shah,Nehal S, AU - Makin,Alistair J, AU - Sheen,Aali J, AU - Siriwardena,Ajith K, PY - 2010/8/24/entrez PY - 2010/8/24/pubmed PY - 2010/12/14/medline SP - 4066 EP - 71 JF - World journal of gastroenterology JO - World J. Gastroenterol. VL - 16 IS - 32 N2 - AIM: To undertake a baseline study comparing quality of life (QoL) in patients with chronic pancreatitis (CP) on Antox to those with CP, matched for disease duration, who were not on this medication. METHODS: CP was defined according to the Zurich classification. Sixty eight consecutive patients with CP who were taking Antox (antioxidants) were compared with 69 consecutive control CP patients not on Antox. European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core questions 30 and Pancreatic Modification (28 questions) were used to assess QoL. Out of a total of 137 patients 28 in each group were matched for disease duration (within 12 mo). Median disease duration was 8 (1-22) years in the Antox group and 7 (1-23) years in the Non-Antox cohort (P = NS, Mann-Whitney U-test). Other parameters (age, gender, etiology, endocrine and exocrine insufficiency) were similar between groups. RESULTS: Median visual analogue pain score in the Antox group was 3 (0-8) compared with 6 (0-8) in the Non-Antox group (P < 0.01). Perceptions of cognitive, emotional, social, physical and role function were impaired in the Non-Antox group compared to Antox patients (P < 0.0001, P = 0.0007, P = 0.0032 and P < 0.005 and P < 0.001, respectively). Analgesics and opiate usage was significantly lower in the Antox group (P < 0.01). Overall physical health and global QoL was better in the Antox group (P < 0.0001, 95% CI: 1.5-3). CONCLUSION: Contemporary quality of life assessments show that after correction for disease duration and cigarette smoking, patients with CP taking antox had better scores than non-antox controls. SN - 2219-2840 UR - https://www.unboundmedicine.com/medline/citation/20731021/Quality_of_life_assessment_in_patients_with_chronic_pancreatitis_receiving_antioxidant_therapy_ L2 - http://www.wjgnet.com/1007-9327/full/v16/i32/4066.htm DB - PRIME DP - Unbound Medicine ER -